Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RNA Editing Therapeutic
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : ARCH Venture Partners
Deal Size : $30.0 million
Deal Type : Financing
AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases
Details : The financing will advance company's pipeline of RNA editing therapeutics driven by its flexible RNA editing platform, RESTORE+TM. AIRNA is advancing development of a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitryp...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : RNA Editing Therapeutic
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : ARCH Venture Partners
Deal Size : $30.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?